<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03139136</url>
  </required_header>
  <id_info>
    <org_study_id>120012A</org_study_id>
    <secondary_id>2016-004038-24</secondary_id>
    <nct_id>NCT03139136</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Efficacy of MBS2320 in Patients With Rheumatoid Arthritis</brief_title>
  <official_title>A 12-Week, Double-Blind, Placebo-Controlled, Phase 2a Study to Investigate the Safety, Tolerability and Efficacy of MBS2320 in Patients With Active Rheumatoid Arthritis Receiving Methotrexate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Modern Biosciences plc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Modern Biosciences plc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rheumatoid arthritis (RA) affects 1 percent of the population worldwide and up to 40 percent
      of patients don't respond to current treatments. MBS2320, the drug being tested in this
      trial, represents a new approach to treating RA, with the potential not only to reduce levels
      of inflammation but to also directly prevent bone damage.The aim of this project is to test
      the safety, tolerability and efficacy of MBS2320 in patients with RA in combination with an
      existing treatment, methotrexate.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rheumatoid Arthritis is a chronic autoimmune disease characterised by synovial inflammation
      and cartilage and bone degradation, leading to joint destruction and progressive disability.

      The aim of the study is to evaluate the safety and tolerability of MBS2320 in patients with
      RA following chronic administration. In addition, the study aims to evaluate the effects of
      MBS2320 on measures of disease activity.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 30, 2017</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-emergent adverse events (safety and tolerability)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Incidence of all grade adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease Activity Score 28 (DAS28)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Disease Activity Score according to the EULAR response criteria</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">108</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>MBS2320</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MBS2320</intervention_name>
    <description>As described in the arm descriptions</description>
    <arm_group_label>MBS2320</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>As described in the arm descriptions</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients of childbearing or non-childbearing potential with with active
             RA, receiving stable once-weekly methotrexate

          -  between 18 and 75 years of age, inclusive.

        Exclusion Criteria:

          -  Patients who are currently pregnant or breastfeeding.

          -  Patients who are being treated with biological or non-biological disease-modifying
             anti-rheumatic drug therapy.

          -  Patients with a history of any other inflammatory or arthritic disease in addition to
             RA that may interfere with the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Inga Bodrug, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Arensia Exploratory Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ezi Otti</last_name>
    <phone>442074440066</phone>
    <email>info@modernbiosciences.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Arensia</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Arensia</name>
      <address>
        <city>Chisinau</city>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Arensia</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Iuliana Chioveanu</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Georgia</country>
    <country>Moldova, Republic of</country>
    <country>Romania</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 26, 2017</study_first_submitted>
  <study_first_submitted_qc>May 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 3, 2017</study_first_posted>
  <last_update_submitted>April 19, 2018</last_update_submitted>
  <last_update_submitted_qc>April 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

